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ABSTRACT
NOTCH REGULATION OF ADAM12 EXPRESSION IN GLIOBLASTOMA
MULTIFORME

SEPTEMBER 2012
ALA’A SALEM ALSYAIDEH, B.V.Sc. JORDAN UNIVERSITY OF SCIENCE AND
TECHNOLOGY, JORDAN
M.S. UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Professor Lisa M. Minter
Glioblastoma is the most common malignant brain tumor, accounting for 17% of
all primary brain tumors in the United States. Despite the available surgical, radiation,
and chemical therapeutic options, the invasive and infiltrative nature of the tumor render
current treatment options minimally effective. Recent reports have identified multiple
regulators of glioblastoma progression and invasiveness. It has been demonstrated that
ADAM12, A Disintegrin And Metalloproteinase encoded by ADAM12 gene, is overexpressed in glioblastoma and directly correlated with tumor proliferation. Additionally,
dysregulation of the Notch signaling pathway has been implicated in the pathogenesis of
many gliomas. Lastly, an evolving role of microRNAs, small noncoding RNAs, in
carcinogenesis is progressively growing. A recent study has identified ADAM12 as a
notch-related gene, and another demonstrated that inhibition of notch signaling decreased
glioblastoma recurrence. However the mechanisms of regulation are still unknown. In
this study, we hypothesize that direct downregulation of microRNA-29, downstream of
over-expression of notch, enhances glioblastoma malignancy through upregulation of
ADAM12. Although our data demonstrate upregulation of Notch1, its downstream target
vi

HES1, and ADAM12 in U87MG glioblastoma cell line. Expression of the cleaved
intracellular Notch1 was not detected. Furthermore, we were unable to demonstrate an
inhibitory effect of ɣ-secretase inhibitor on Notch signaling, likely reflecting the
requirement for modifying culturing conditions or detection in our assays. Furthermore,
miR-29 was detected in glioblastoma cells. The expression of miR-29 was further
elevated by ɣ-secretase inhibitor treatment, suggesting a role for Notch1 inhibition on
miR-29 expression. Although no conclusive results are shown in our work, a role of
Notch1 through miR-29 is implicated in the pathogenesis of glioblastoma pathogenesis
warranting further investigation into the role downstream target genes in the Notch
signaling pathway.
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CHAPTER 1
THE ROLE OF NOTCH SIGNALING IN THE PATHOGENESIS OF
GLIOBLASTOMA MULTIFORME
1.1. Glioblastoma
1.1.1. Introduction
Gliomas are heterogeneous brain tumors with cellular features of glial cells and
include astrocytomas, oligodendrogliomas, ependymoma, and mixed gliomas. Among the
most aggressive subtypes is Glioblastoma Multiforme (GBM), the most aggressive of
astrocytomas classified as Grade IV astrocytic neoplasm according to World Health
Organization (WHO) (Louis et al., 2007). Histologically, GBM is characterized by
increased cellularity, nuclear atypia, and mitotic activity similar to Grade III Anaplastic
Astrocytoma, in addition to microvascular proliferation and necrosis unique to GBM
(Figure 1) (Wen and Kesari, 2008). GBM is the most common primary brain neoplasm
usually found in the cerebral hemispheres, but may also occur in the cerebellum,
brainstem, or spinal cord (Schwartzbaum et al., 2006). Depending on the involved brain
site, the most common clinical signs include seizures, headaches, and focal neurologic
deficits. GBM accounts for 80% of all malignant brain tumors (CBTRUS, 2010). The
causes of GBM are currently unknown; however, multiple risk factors, molecular
pathways, and potential etiologies have been implicated in cellular transformations and
tumorigenesis. Alcohol consumption, ionizing radiation, Simian virus 40 (SV40), and
cytomegalovirus are among the most recent factors implicated in GBM pathogenesis
(Baglietto et al., 2011; Cavenee, 2000; Dziurzynski et al., 2012; Vilchez et al., 2003).
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Due to its infiltrative and necrotic potentials in addition to the uncontrolled cellular
proliferation, angiogenesis, and resistance to apoptosis, GBM is associated with very
poor prognosis (Furnari et al., 2007), with survival rates of only 4.5% or less (CBTRUS,
2010). Although combination of surgical, radiotherapy, and chemotherapy exists, the
infiltrative nature of GBM leads to incomplete recovery and frequent fatal tumor relapse.
This is primarily due to the difficulty in overcoming resistant cancer stem cells (CSCs).
1.1.2. Cellular Origin
GBM is composed of a mixed population of cell types that includes astrocyte-like
and stem-like cells. The cellular origin of GBM is a controversial topic in glioma cancer
research, and a continuous interest in GBM ontogeny is stimulated for the possibility of
better understanding of fundamental pathways necessary for GBM development that
could aid in improving diagnostic and therapeutic solutions (Visvader, 2011). One of the
most significant recent advances in this regard is the discovery of cancer stem cells
(CSC). For those pertaining to GBM, CSCs share multiple features with those found in
normal neural stem cells and progenitor cells, such as self-renewal, marker expression,
multilineage differentiation, and localization to stem cell microenvironment niches (Sanai
et al., 2005). More recently, by introduction of genetic mutations into neural stem cells,
several studies have supported the notion of neural stem cells in the production of GBM
(Bachoo et al., 2002; Zheng et al., 2008; Zhu et al., 2005). Moreover, neural stem cells
are probably target cells for malignant transformation, and the wide range in GBM
heterogeneity represents different stages of neural stem cell differentiation hierarchy.
Regardless, common features need to be met for a cell to be considered glioma CSC
(Rich, 2008), which include capability of self-renewal, high proliferative potential, and
when injected in xenograft models to initiate tumorigenesis. Despite the scientific
2

advances, it’s currently debatable whether CSCs originate from neural stem cells. CSCs
are identified immunocytochemically by expression of CD133 (Assanah et al., 2006;
Beier et al., 2007; Kesari and Stiles, 2006; Singh et al., 2004), and constitute a minority
of the GBM cell population. Despite that, they play a critical role in tumor generation and
maintenance, and contribute to tumor resistance to standard treatments (Dirks, 2008;
Vescovi et al., 2006).
1.1.3. Molecular Pathogenesis
The mechanism of glial transformation is the result of cumulative genetic
mutations and growth-factor signaling pathway dysregulation. Dysregulated signaling
pathways frequently result in transcriptional activation of survival, proliferation,
invasion, and angiogenesis pathways (Figure 2).
1.1.3.1. Growth Factor Overexpression and Apoptosis
Expression of both growth factors and their receptors is common in GBM and sets
up an autocrine growth-promoting loop. The most common signaling defects occur in
those that involve Epidermal Growth Factor Receptor (EGFR) and Platelet-derived
Growth Factor Receptor (PDGFR) (Furnari et al., 2007). The A chain of PDGF and its
cognate alpha receptor are overexpressed in the majority of diffuse astrocytic tumors
(Hermanson et al., 1992). Amplification of EGFR expression on the other hand occurs
primarily in GBM (Wen and Kesari, 2008). Upregulation of EGFR is reported in 40-50%
of GBM patients, and half of those express a constitutively autophosphorylated EGFRvIII
variant (Furnari et al., 2007; Pelloski et al., 2007). Aberrant growth factors result in
activation of intermediate signal-transduction pathways; most commonly the Ras–
mitogen-activated protein (MAP) kinase pathway involved in proliferation and cell cycle
progression, the phosphatidylinositol 3-kinase (PI3K)–Akt–mammalian target of
3

rapamycin (mTOR) pathways leading to the inhibition of apoptosis and enhancing
cellular proliferation, and the inactivation of tumor-suppressor gene PTEN which
negatively regulates the PI3K pathway (Furnari et al., 2007).
1.1.3.2. Aberrant Cell Cycle
Like other cancers, perturbations of p53- and Rb-mediated cell cycle regulation
occur commonly in GBM. p53 protein normally inhibits cell cycle progression and
induces apoptosis in response to DNA damage, and hence inactivation of p53 function
leads to cell cycle dysregulation. Mutation in p53 is reported in approximately 25% of
GBMs (Fulci et al., 1998). Aberrant loss of Rb and other components of the
p16/cdk4/cyclinD/pRb G1 to S phase transition cell cycle regulation are frequently
observed in GBM and other astrocytic tumors. Mutation in Rb occurs in 30–40% of
GBMs, and mutation in p16 occurs in 33% of GBM. Disturbance of this check point
results in uncontrolled cell cycle and progression of tumor formation.
1.1.3.3. Angiogenesis and Invasion
GBM is a markedly vascularised cancer and characterized by significant
invasiveness of the surrounding brain parenchyma. This is heavily regulated through
crosstalk between growth factors, extracellular matrix proteins, integrins, proteinases, and
tissue microenvironment. Angiogenic and invasive features of GBM result from a
combination of stimulating factors, such as activation of vascular endothelial growth
factor (VEGF) and Matrix Metalloproteinases (MMPs) (Guo et al., 2003; Jain et al.,
2007), that aid in neovascularization and breakdown of impeding extracellular matrix
proteins, and degradation of normally inhibiting factors, such collagen, leading to local
tumor spread and access to the systemic circulatory system.
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1.1.3.4. Other signaling pathway
Other developmental pathways that contribute to the biologic features of gliomas
are those involving Notch, sonic hedgehog, wingless, CXC chemokine receptor 4
(CXCR4), and bone morphogenetic proteins (Lee da and Gutmann, 2007). In the
following section, we will review details on Notch biology and its contribution to GBM
tumorigenesis.
1.2. Notch
1.2.1. Biology
The “Notch” family of proteins was initially identified by Thomas Morgan in
Drosophila melanogaster in 1917. Mutation in the genes encoding Notch proteins
resulted in ‘notches’ at the wing margin of adult flies, hence inspiring the Notch name
(Morgan, 1917). Notch proteins are type I transmembrane receptors consisting of 36
ligand binding epidermal growth factor (EGF)-like tandem repeats and 3 LIN-12/Notch
(LIN) repeats in the extracellular domain. The intracytoplasmic domain contains RBPJκbinding (RAM) domain, six tandem ankyrin (ANK) repeats, a transcription activation
domain (TAD) and a proline/glutamate/serine/threonine-rich (PEST) sequence (Figure 3)
(Tsukumo and Yasutomo, 2004). Notch receptor is cleaved post-translationally at site S1
and heterodimerized between two extracytoplasmic juxtamembrane regions that form
both N-terminal and C-terminal heterodimerization domains (HD-N and HD-C,
respectively) to generate a fully mature receptor. In vertebrates, four Notch paralogs are
encoded (Notch 1-4), with Notch1 and Notch2 showing high homology with Drosophila
Notch, and Notch3 and Notch4 are more distantly related, with 34 and 29 EGF-like
repeats, and are devoid of TAD domains (Lardelli et al., 1994; Uyttendaele et al., 1996;
Weinmaster et al., 1991; Weinmaster et al., 1992).
5

1.2.2. Notch signaling
In mammals, Notch receptors are activated by five type I transmembrane ligands,
three Delta-like (Dll1, Dll3 and Dll4) and two Serrate/Jagged (Jag 1 and Jag2) (Figure 3)
(Artavanis-Tsakonas et al., 1999).
Notch activation results from ligand-mediated cleavage at sites S2 or S3 (Figure
4). Activation of Notch from cleavage at site S3 within the transmembrane domain is
mediated by gamma-secretase (De Strooper et al., 1999). Receptor activation leads to
release of Notch intracellular domain (NICD), which translocate to the nucleus.
Thereafter, intranuclear NICD binds Su(H)/CSL/CBF1/RBPJκ to trans-activate target
genes such as HES and HEY families of basic helix-loop-helix transcription factors
(Artavanis-Tsakonas et al., 1995; Artavanis-Tsakonas et al., 1999; Jarriault et al., 1995).
Cleavage of Notch at site S2 is mediated by an ADAM metalloprotease and TNF-αconverting enzyme (TACE) (Brou et al., 2000), and leads to the release of a soluble form
of Notch named Notch extracellular truncation (NEXT) (Mumm et al., 2000).
Non-canonical Notch signaling can occur independent of RBPJκ, presumably
through a Deltex-dependent alternative pathway (Matsuno et al., 1998; Ramain et al.,
2001). In T helper (Th) cells, Jagged mediates Th2 cell differentiation by triggering the
RBPJκ-dependent canonical pathway, while Dll1 instructs Th1 commitment in an
RBPJκ-independent fashion (Amsen et al., 2004).
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1.2.3. Notch in Brain Development
The Notch signaling pathway plays a fundamental role in the regulation of several
developmental processes such as proliferation, stem cell maintenance, differentiation
during embryonic development and homeostasis of adult self-renewing organs (Bray,
2006; Wen and Kesari, 2008). Canonical and non-canonical Notch signaling pathways
have been shown to target several genes involved in brain development. The canonical
pathway has been shown to target GFAP (Ge et al., 2002), HES1 (Wu et al., 2003),
HEY1 (Zavadil et al., 2004), BLBP (Patten et al., 2003), NESTIN (Shih and Holland,
2006), and TNC genes (Sivasankaran et al., 2009), while the non-canonical pathway has
been shown to target ERBB2 (Patten et al., 2006). Most importantly, Notch1 induces
TP53-dependent EGFR expression (Purow et al., 2008), the most common signaling
defect in GBM.
In addition to the “notched” winged observed in Drosophila melanogaster with
mutated Notch genes, several studies have demonstrated the role of Notch in
neurogenesis. In loss-of-function experiments, a defective neuroectodermal development
was observed, with the development of an embryonic phenotype characterized by
expanded population of neuroblasts at the expense of epidermal cells (Poulson, 1937).
This indicated that Notch is an antineurogenic factor required to control cell fate decision
by preventing the differentiation into neuroblasts. Gain-of-function mutation in Notch
gene further supported the antineurogenic role of Notch during Drosophila development
(Brennan et al., 1997; Rebay et al., 1993).
Distinct patterns of Notch expression are seen in rodents. While notch1, notch2,
and notch3 transcripts are commonly present in the germinal zones of late embryonic and
postnatal brains, notch2 expression persists in the postnatal mouse brain in immature glial
7

cells (Higuchi et al., 1995; Irvin et al., 2001; Tanaka et al., 1999). Consistent with the
antineurogenic role of Notch signaling in Drosophila, it appears that high expression of
Notch2 is required for the prevention of neuronal differentiation and the maintenance of
neural stem cell (NSC). Activation of Notch promoted gliogenesis at the expense of
neurogenesis (Morrison et al., 2000), and suppressed neuronal differentiation of NSCs by
maintaining their proliferation (Hitoshi et al., 2002; Shimizu et al., 2008; Solecki et al.,
2001). These observations suggest a role for Notch signaling in the maintenance of GBM
CSC.
While knockout of Notch1 and Notch2 in results in embryonic and perinatal
lethality, mutations in Notch have been associated with neurological and vascular
abnormalities in humans (Garg et al., 2005; Joutel et al., 1996). The fact that the Notch
signaling pathway is involved in several developmental processes and that inactivation of
Notch results in constant defects in angiogenesis implicate a possible role for Notch
signaling in tumorigenesis and tumor neovascularization. This is evident in the role of
Notch1 and Notch2 mutations found in acute T cell lymphoblastic leukemia (T-ALL) and
a fraction of B cell lymphomas, respectively (Ellisen et al., 1991; Lee et al., 2009).
1.2.4. Notch in Glioblastoma
Notch signaling is one of the major pathways involved in GBM development, and
expression of Notch proteins and their ligands are critical markers of GBM survival and
proliferation (Boulay et al., 2007; Purow et al., 2005).
Notch1 and Notch2 are highly expressed in GBM and astrocytoma (Sivasankaran
et al., 2009). Notch2 has been suggested to drive embryonic brain tumor growth (Solecki
et al., 2001), with high expression in GBM (Sivasankaran et al., 2009). Through TP53,
Notch1 was shown to regulate transcription of the EGFR gene, the major proliferation
8

pathway in GBM (Purow et al., 2008), with overexpression of Notch signaling mediator
genes in the molecular subset of GBM with EGFR amplification (Brennan et al., 2009).
In contrast, a minor subset of GBM with slower GBM progression and better patient
prognosis are associated with impaired Notch2 signaling and impaired Notch-mediated
GBM invasiveness (Boulay et al., 2007; Sivasankaran et al., 2009). The role of Notch
was further supported by loss-of-function and gain-of-function experiments. While
inhibition of Notch signaling by the use of ɣ-secretase inhibitors (GSIs) resulted in
reduction in GBM CSC proliferation and increased apoptosis, while expression of an
active form of Notch2 increased tumor growth (Fan et al., 2009). Interestingly, in vivo
delivery of GSI consistently blocked tumor growth, and significantly prolonged patient
survival (Fan et al., 2009). Through the inhibition of Notch signaling, GSI treatment
significantly reduced radioresistance of GBM CSC (Wang et al., 2009).
Additionally, Notch-RBPJκ transactivates tenascin-C (Sivasankaran et al., 2009),
a highly expressed extracellular matrix glycoprotein that increases during progression of
GBM and used as a prognostic marker for GBM patient survival (Garcion et al., 2001;
Leins et al., 2003).
1.3. MicroRNAs
1.3.1. Signaling and processing of miRNAs
MicroRNAs (miRNAs) are a non-coding class of RNAs, 20-25 nucleotides in
length that do not result in proteins. MicroRNAs modulate gene expression through base
pairing between the seed sequence of the miRNA (nucleotides 2-8 at its 5' end) and their
complementary match sequence at the 3' UTR region of target mRNAs (Bartel, 2009).
Cognate binding of miRNA to its target mRNA results in translation suppression or direct
degradation of targeted mRNA (Kolfschoten et al., 2009). MicroRNAs are first
9

transcribed as long (~ 250 nts) primary transcripts (pri-miRNA) that fold into hairpin-like
structures. Following transcription, primary transcripts are processed in the nucleus by
the Drosha complex into pre-miRNAs (~120 nts) and transported to the cytoplasm by
exportin 5. In the cytoplasm, pre-miRNAare further processed by Dicer ribonuclease
(Carthew and Sontheimer, 2009), in which mature miRNAs are incorporated into the
RNA-induced silencing complex (RISC) in association with Argonaute proteins. Singlestranded miRNA is unwound by Dicer, which also guides target selection, inhibiting the
translation, and stability and/or localization of target mRNA (Brodersen and Voinnet,
2009; Kim et al., 2009; Zheng et al., 2008). MicroRNA biogenesis and mRNA binding is
illustrated in figure 5.
1.3.2. Structure and function of the miR-29 family
The microRNA-29 (miR-29) family in human consists of four members: miR29a, miR-29b1, miR-29b2, and miR-29c. They are encoded by two gene clusters, MIR29B1-MIR-29A and MIR-29B2-MIR-29C located in chromosome 7 (chr.7q32.3) and
chromosome 1 (chr.1q32.2), respectively (Kriegel et al., 2012). miR-29b1 and miR-29b2
are identical, but they are distinguished from each other due to their chromosomal
location. The distance between the two miRNAs in each cluster is less than 1kb (Chang et
al., 2008; Eyholzer et al., 2010; Mott et al., 2010), and miR-29b1 and miR-29b2 are
upstream of miR-29a and miR-29c, respectively the gene sequences are highly conserved
between humans, rats and mice. The mature sequences of miR-29a and miR-29c are 22
nucleotides long while miR-29b1/b2 have identical mature sequences and are 23
nucleotides long. Each of miR-29 members have the same short seed sequence;
AGCACC between positions 2 to 7 in each mature sequence. Consequently, it is
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predicted that all miR-29 members target the same set of genes. The structures of premiR-29 and mature miR-29 are shown in Figure 6.
1.3.3. The miR-29 family in tumorigenesis
Similar to mRNAs encoding for proteins, miRNAs have well-defined
developmental and cell-type-specific expression patterns, and may be involved in tumor
suppression or tumor malignancies (Havelange et al., 2009).
Loss of miR-29 function has been associated with several tumors. Mutated miR29b has been shown in leukemia, and mutation repair prevented the ability of leukemia
cells from growing in an immunodeficient mouse host (Havelange et al., 2009).
Upregulated miR-29a and miR-29b were also found in B-cell Chronic Lymphocytic
Leukemia (CLL) (Santanam et al., 2010). Elevated miR-29a expression and
downregulation of miR-29b were found in primary Acute Myeloid Leukemia (AML)
(Garzon et al., 2008; Han et al., 2010). Reduced expression of miR-29b has been
observed in hepatocellular carcinoma and is significantly associated with poor prognosis.
Re-introduction of miR-29a/b/c induced apoptosis of cancer cells and repressed
tumorigenicity (Xiong et al., 2010). miR-29b was similarly found downregulated in
cholangiocarcinoma cell lines (Mott et al., 2007). Furthermore, miR-29 was found to
function in myogenesis and is epigenetically silenced in rhabdomyosarcoma cell lines
(Wang et al., 2008). Upregulation of miR-29a/b/c expression was also found in
pancreatic endocrine tumors (Roldo et al., 2006).
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Figure 1: Histological features of Glioblastoma Multiforme. Panels A and B show the
histologic appearance of a glioblastoma, characterized by nuclear pleomorphism, dense
cellularity, and pseudopalisading necrosis (asterisk) (Panel A, hematoxylin and eosin), as
well as vascular endothelial proliferation (asterisk) and mitotic figures (arrows) (Panel B,
hematoxylin and eosin) (Wen and Kesari, 2008).
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Figure 2: Major Signaling Pathways in Malignant Gliomas and the Corresponding
Targeted Agents in Development for Glioblastoma (Wen and Kesari, 2008).
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Figure 3: Ligands, structure and processing of Notch1 receptor. Left: the Delta-like
ligand (Dll) and Serrate-Jagged ligand (Jag) structural subsets of Notch ligands. Right:
structure of Notch1 receptor resulting from post-translational cleavage at site S1 and
heterodimerization of the cleaved parts. Ligand-dependent cleavages at sites S2 and S3
generate soluble Notch extracellular truncation (NEXT) and cytosolic Notch intracellular
domain (N-IC) forms, respectively (Lino et al., 2010).
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Figure 4: Sequential events and control of Notch expression and signaling (Osborne
and Minter, 2007).
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Figure 5.Schematic of microRNA biogenesis. (A) Biogenesis of a miRNA-induced
silencing complex (RISC). (B) Binding of microRNA to the 3'-UTR of mRNA (Liu,
2009).
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Figure 6: Structure of pre-miR-29 and mature miR-29 family of microRNAs. The structure of (A) miR-29a, (B) miR-29b and (C)
miR-29c.
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1.4. AIM of the study
1.4.1. Rationale
Recent reports have identified multiple regulators of glioblastoma progression and
invasiveness.

It

has been

demonstrated that

ADAM12,

A

Disintegrin

and

Metalloproteinase encoded by ADAM12 gene, is over-expressed in glioblastoma and
directly correlated with tumor proliferation. Additionally, dysregulation of the Notch
signaling pathway has been implicated in the pathogenesis of many gliomas. Lastly, an
evolving role of microRNAs in carcinogenesis is progressively growing. A recent study
has identified ADAM12 as a Notch-related gene, and another demonstrated that inhibition
of Notch signaling decreased glioblastoma recurrence. However the mechanisms of
regulation are still unknown.
1.4.2. Hypothesis
In this study, we hypothesize that direct downregulation of microRNA-29,
downstream of over-expression of Notch, enhances glioblastoma malignancy through
upregulation of ADAM12.
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CHAPTER 2
RESULTS

2.1. Assay optimization for the detection of Notch1 in GBM cell line
For optimal detection of Notch1 and ADAM12 in GBM cell line, U87MG cells
were plated at different cellular density at two culture durations. Cells were cultured at
0.25X106, 0.5X106, and 1X106 cells per well in 6-well plates and were incubated at
37˚C/5%CO2 for 24 hours and 48 hours. Cells were harvested and examined by trypan
blue viability assay as indicated in the Materials and Methods section.
As shown in Table 1, all culture conditions resulted in an increase in the total
number of cells after 24 and 48 hours of culture initiation. While the percent viability was
high in all conditions, initial culture start of 0.25X106 cells for 24 hours results in the
most remarkable cell death and lowest viability percentage at 57.1% despite the increase
in total number of cells 24 hours post culture initiation. Viability percentage of initial
0.25X106 cells condition was higher at 48 hours post culture initiation. Culturing cells at
0.5X106 and 1X106 resulted in cellular expansion and comparable high viability rates at
both 24 and 48 hours.
2.2. Expression of Notch1, ADAM12, and miR-29 in GBM cell line
The Notch signaling pathway has been implicated in the pathogenesis of GBM.
To examine the expression of Notch signaling pathway components in U87MG GBM cell
line, Notch1, HES1, and c-myc expression levels were determined at the protein and
mRNA levels. Additionally, ADAM12 expression levels were determined to correlate
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their expression levels with components of the Notch signaling pathway. Cell culture
conditions of 0.3X106 per well were plated in a 6-well plate and incubated for 24, 48, and
72 hours to monitor the differential Notch1 and ADAM12 protein expressions at different
time points (Figure 7). Notch1-specific antibody used in these verification experiments is
able to detect the C-terminus of Notch1 present in uncleaved Notch1 and the
transmembrane domain post Notch1 activation. Our ADAM12-specific antibody is able
to detect both the long and short forms of ADAM12 . Jurkat cells were used as a positive
control for the detection of Notch1 and ADAM12, and DO11.10 were used as a negative
control for Notch1 expression.
Both total Notch1 (300kDa, not shown) and the cleaved transmembrane domain
of Notch1 (120kDa) were detected at all time points in both the GBM U87MG cell line
and in the positive control Jurkat cell line. Two bands were present in the negative
control DO11.10 cell line; however, these bands don’t correspond to the expected band
sizes of Notch1 and hence likely represent non-specific cross reactivity. The downstream
components of the Notch signaling pathway, HES1 and c-myc, were detected in U87MG
cell line by western blot analysis (data not shown). ADAM12 was equally detected at all
time points, correlating with the upregulated expression of Notch signaling pathway
components. Adequate protein extraction and equal protein loading per lane were
confirmed by the strong and equal band density of the positive internal control β-Actin.
To verify the activity of the Notch signaling pathway at the transcriptional levels,
mRNA expression of NOTCH1, HES1, and the long (ADAM12L) and short (ADAM12S)
forms of ADAM12 were measured using the same culture conditions (Figure 8).
NOTCH1, HES1, ADAM12L, and ADAM12S were detected to levels comparable to the
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positive internal control β-ACTIN, indicating the activation of these genes in U87MG
GBM cell line. Transcript levels of all genes remained relatively constant at 24, 48, and
72 hours post culture initiation. ADAM12L expression was higher compared to ADAM12S
and NOTCH1, the latter of which had comparable expression levels.
We further demonstrated the specificity and sensitivity of our culture conditions
and assay design for the detection of members of the miR-29 family, miR-29a, miR-29b,
and miR-29c, a group of microRNAs that are modulated by Notch1 activation in certain
types of tumors (Figure 9). Sno202 was used as an internal control, and it was detected in
all culture conditions. All members of the miR-29 family were detected in our assay to
levels below sno202. When compared to each other, levels of miR-29a, miR-29b, and
miR-29c were comparable at all time points. In general, the expression levels of all miR29 members were approximately 50% of the expression level of the internal control
sno202.
Repetition of the same quantitative RT-PCR work with lower cell density per well
at 0.2X106 cells per well in 6-well plate resulted in similar expression levels of NOTCH1,
HES1, ADAM12L, and ADAM12S (Figure 10). Although miR-29 expression was detected
at lower cell culture density, the expression levels were nearly 1.3 fold higher compared
to their corresponding expression levels at 0.3X106 cells per well. Despite lower viability
rates at lower cell density, expression levels remained comparable between the two
culture conditions. Regardless, our results demonstrate that our culture conditions and
detection assays are sufficient and capable of detecting variable protein and transcript
levels of Notch1, HES1, ADAM12, and members of miR-29 family.
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2.3. The effect of gamma-secretase inhibitor on the expression of Notch1, HES1,
ADAM12, and miR-29 in GBM cell line
To explore the regulation of Notch signaling pathway in GBM, we treated
U87MG GBM cell line with ɣ-secretase inhibitor (GSI), an inhibitor of Notch cleaving
enzyme ɣ-secretase, and measured gene transcription levels of components of the Notch
signaling pathway. Using western blot analysis, full-length Notch1 and the cleaved
transmembrane component of Notch1 were readily expressed in U87MG cells (Figure
11). The cleaved intracellular component of Notch1 however was not detected. Similarly,
ADAM12 was detected in cells. Treatment of cells with GSI did not affect the protein
expression levels of Notch1 or ADAM12. Repeating the same experiment at longer
durations of 48h and 72h with longer and higher concentrations of GSI treatment did not
result in any difference in the Notch1 and ADAM12 expression levels, and the cleaved
intracellular domain remained undetectable.
To verify the effectiveness of GSI treatment, similar conditions were carried out
on Jurkat cell line, cells known to constitutively express high levels of the cleaved
intracellular component of Notch1 and respond to GSI treatment (Figure 12A). Indeed,
the cleaved intracellular component of Notch1 was detected in untreated Jurkat cells.
Moreover, treatment of cells with multiple preparations of GSI resulted in significant
downregulation of the cleaved intracellular component of Notch1 as expected. These
results demonstrate that our culture setup and treatment are functioning properly. We
then tested the same GSI preparations on U87MG GBM cell line (Figure 12B). While the
Notch1 and ADAM12 were expressed, the cleaved intracellular component of Notch1
was not expressed. Furthermore, treatment of cells with different GSI preparations for
48h did not result in changes in the levels of Notch1 or ADAM12 expression. These
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results demonstrate that Notch1 has been cleaved, as detected by the cleaved
transmembrane component, the cleavage of Notch1 did not result in an intracellular
component, suggesting one of the following scenarios: (1) that cleaved intracellular
component of Notch1 rapidly degraded to levels below our assay limits of detection in
whole cell lysate and that Notch1 enrichment in nuclear protein fraction is necessary for
the detection of low levels of cleaved intracellular Notch1, or that (2) Notch1 was
cleaved at a site alternative to V1744, rendering our detecting monoclonal antibody nonspecific for the detection of newly formed cleaved Notch1 in our western blot analysis.
To further investigate the expression of the Notch signaling pathway at the
transcriptional levels using our quantitative RT-PCR assay. Relative to β-ACTIN
expression, the expression of NOTCH1 transcript levels increased with GSI treatment
(Figure 13A). NOTCH1 expression levels were highest at 72h post treatment, with
expression levels at least 4 fold higher compared to β-ACTIN expression and 10 fold
higher with 50µM GSI treatment. The expression of HES1, ADAM12L, and ADAM12S
were similar to those seen with NOTCH1. HES1 expression was 3-20 fold higher than βACTIN expression, particularly with 5µM and 50µM GSI treatment at 24h and 72h post
treatment (Figure 13B). Levels of ADAM12L were at least 2 fold higher than β-ACTIN
expression; however, this was only seen with 72h of culture treatment (Figure 13C).
ADAM12S was similarly expressed at high levels, particularly with 5µM and 50µM GSI
treatment at all time points (Figure13D). These results demonstrate difference between
the transcriptional and protein levels of the examined genes, and indicate that the mode of
regulation in U87MG GBM cell line needs to be explored.
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In an attempt to investigate the regulation of the aforementioned genes, we
measured the expression levels for members of the miR-29 family. Levels of miR-29a,
miR-29b, and miR-29c were constantly elevated compared to the internal control (Figure
14). Levels of miR-29b and miR-29c at 72h post treatment were the highest. Although
further work is needed to investigate the nature of miR-29 involvement in GBM
pathogenesis, the elevated levels of miR-29 members support their role in GBM
pathogenesis.
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Table 1. Viability Assay of U87MG cell line at 24 and 48 hour.
24 HOUR CULTURE
ORIGINAL
NUMBER

TOTAL
LIVE

TOTAL
DEAD

TOTAL
ALL

% VIABLE

%
DEAD

0.25X106

2.0X105

1.5X105

3.5X105

57.1

42.9

0.5X106

5.5X105

1.0X105

6.5X105

84.6

15.4

1.0X106

1.1X106

7.5X104

1.1X106

93.3

6.7

48 HOUR CULTURE
ORIGINAL
NUMBER

TOTAL
LIVE

TOTAL
DEAD

TOTAL
ALL

% VIABLE

%
DEAD

0.25X106

3.5X105

1.0X105

4.5X105

77.8

22.2

0.5X106

5.8X105

5.0X104

6.3X105

92.0

8.0

1.0X106

1.2X106

2.5X105

1.5X106

83.1

16.9
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Figure 7: Expression of Notch1 and ADAM12 in U87MG GBM cell line. Western
blot analysis of protein levels of Notch1 and ADAM12 in U87MG GBM cell line at 24h,
48h, and 72h of culture. Jurkat cells were used as a positive control for the expression of
Notch1 and ADAM12 and DO11.10 cells were used as a negative control for the
expression of Notch1.
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Figure 8: Expression of NOTCH, HES1, and ADAM12 in U87MG GBM cell line.
Quantitative RT-PCR analysis of transcription levels of NOTCH1, HES1, and ADAM12
in U87MG GBM cell line at 24h, 48h, and 72h of culture. Results were generated from 3
independent experiments, calculated by the ΔΔCT method, and normalized to β-Actin.
Each bar represents the mean ± standard error of the mean [SEM].
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Figure 9: Expression of miR-29 family in U87MG GBM cell line. Quantitative RTPCR analysis of transcription levels of miR-29a, miR-29b, and miR-29c in U87MG
GBM cell line at 24h, 48h, and 72h of culture. Results were generated from 3
independent experiments, calculated by the ΔΔCT method, and normalized to sno202.
Each bar represents the mean ± standard error of the mean [SEM].
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Figure 10: Expression of NOTCH1, HES1, ADAM12, and miR-29 family at two
different cell densities of U87MG GBM cell line. Quantitative RT-PCR analysis in
U87MG GBM cell line at 0.2X106 and 0.3X106 cells per well. Results were generated
from 3 independent experiments, calculated by the ΔΔCT method. mRNA data were
normalized to β-ACTIN, and miRNA data were normalized to sno202. Each bar
represents the mean ± standard error of the mean [SEM].*P <0.05; *** P <0.001; ****
P <0.0001
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Figure 11: Effect of GSI on the expression of Notch1, cleaved intracellular Notch1,
and ADAM12 in U87MG GBM cell line. Western blot analysis of protein levels of
Notch1, cleaved intracellular Notch1, and ADAM12 in U87MG GBM cell line at 24h,
48h, and 72h of culture treated with 5, 10, 20, and 50µM of DAPT-GSI. Jurkat cells were
used as a positive control for the expression of Notch1, cleaved intracellular Notch1, and
ADAM12L and DO11.10 cells were used as a negative control for the expression of
Notch1.
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Figure 12: Effects of different GSI preparations on Notch1 activation.(A)Western
blot analysis of protein levels of cleaved intracellular Notch1 in Jurkat cell line at 24h of
culture treated with 10 and 50µM of two preparations of DAPT-GSI and one preparation
of IL-CHO-GSI.(B) Western blot analysis of protein levels of Notch1, cleaved
intracellular Notch1, and ADAM12 in U87MG GBM cell line at 48h of culture treated
with 5, 25 and 50µM of DAPT-GSI and IL-CHO-GSI.
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A

B

C

D

Figure 13: Effects of GSI on the expression of Notch1, cleaved intracellular Notch1,
and ADAM12 in U87MG GBM cell line. Quantitative RT-PCR analysis in U87MG
GBM cell line at 0.3X106 cells per well and treated with 5, 25, and 50µM DAPT-GSI for
24h, 48h, and 72h. Results were generated from 3 independent experiments, calculated by
the ΔΔCT method and normalized to β-Actin. Each bar represents the mean ± standard
error of the mean [SEM].
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A

B

C

Figure 14: Effects of GSI on the expression of miR-29 in U87MG GBM cell line.
Quantitative RT-PCR analysis in U87MG GBM cell line at 0.3X106 cells per well and
treated with 5, 25, and 50µM DAPT-GSI for 24h, 48h, and 72h. Results were generated
from 3 independent experiments, calculated by the ΔΔCT method and normalized to
sno202. Each bar represents the mean ± standard error of the mean [SEM].
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CHAPTER 3
DISCUSSION AND CONCLUDING REMARKS

The association of Notch signaling pathway with the pathogenesis of many types
of cancers has been previously demonstrated (Leong and Karsan, 2006). Here, we
investigated Notch1 regulation of ADAM12 in the U87MG Glioblastoma cell line, to aid
in our understanding of the pathogenesis of GBM, the most malignant type of brain
cancer. We demonstrated elevated levels of Notch1, HES1, c-Myc, and ADAM12
expression levels in U87MG GBM cell line, indicating that the Notch signaling pathway
is activated in GBM and correlates with the expression level of ADAM12 protein
expression. We further confirmed the elevated expression of NOTCH1, HES1, and
ADAM12 in GBM cell line at the transcriptional level using quantitative RT-PCR.
To examine the downstream components of the Notch signaling pathway, we
examined the expression levels of cleaved intracellular Notch1, HES1, and ADAM12.
While our results demonstrated that Notch1 had been cleaved, as detected by the cleaved
transmembrane component, we were unable to detect cleaved intracellular component,
suggesting a dysfunction in the cleavage at the S2 cleavage site limiting the exposure of
S3 cleavage site and resulting in a cleaved transmembrane with absence of the
intracellular domain. Alternatively, there might be a different species of intracellular
cleaved Notch that might have resulted from cleavage at a site different from the
originally accepted V1744 site (Tagami et al., 2008), resulting in failure of our antibody,
which only detects Notch1 cleaved at V1744, to detect the intracellular cleaved form of
Notch1. Transcriptional levels of these genes on the other hand were elevated with
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treatment of GSI, an inhibitor of intracellular Notch cleavage, indicating an upregulation
of gene expression with post-transcriptional suppression of translation. The difference
between the transcriptional and protein levels of the examined genes requires additional
exploration of the mode of regulation in GBM. Furthermore, multiple types of GSI
investigational drugs exist that potentially target different isoforms of ɣ-secretase present
in GBM cell lines and different from those present in our Jurkat cells positive control
(Kopan and Ilagan, 2009). Alternative experimental approaches can be potentially used to
suppress Notch signaling pathway, such as siRNA against Notch mRNA or the
expression of dominant negative form of Notch coactivator mastermind-like 1 (Chen et
al., 2010).
Similarly, transcriptional levels of miR-29 members were elevated in U87MG
GBM cell line, indicating their involvement in GBM pathogenesis. It is possible that the
elevated miR-29 levels results in posttranscriptional suppression of ADAM12 translation,
hence explaining the elevated ADAM12 transcripts with no demonstrable elevation of
ADAM12 protein levels upon GSI treatment. A similar mechanism might be involved in
the regulation of Notch1 translation.
The involvement of Notch signaling pathway in brain development and cancer is
highly context-dependent (Lardelli et al., 1994). Previous reports have demonstrated the
differential expression of various Notch signaling components in GBM (Chen et al.,
2010). Although all cell lines used were derived from GBM patients, the role of Notch
signaling differed according to GBM subtype. In contrast to our results, Notch2 was the
predominant Notch type involved in the majority of GBM subtypes, including U87 cell
line. Notch1 expression was predominant in only 2 of the 5 cell line examined. While the
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authors demonstrated the biological effect of Notch signaling on tumor growth and
neurosphere formation, they similarly failed to present the expression of cleaved
intracellular Notch domain. It is then likely that Notch exerts its function in GBM
through a different pathway that does not induce the expression of cleaved intracellular
Notch domain, or that we are temporally unable to detect that component in our culture
conditions due to a short half-life of the cleaved protein.
Other studies have indicated that Notch signaling increases neurosphere formation
(Fan et al., 2010; Gilbert et al., 2010; Jeon et al., 2008), the cancer stem cell component
of GBM, indicating the need to test our parameters in neurosphere culturing conditions,
which include serum depletion of culture media and longer culturing durations of up to
10 days.
In all, our study supports the role of Notch signaling pathway in GBM
pathogenesis and support further investigation in the role of ADAM12 and miR-29 in the
pathogenesis of GBM.
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CHAPTER 4
MATERIALS AND METHODS

4.1. Cell Culture
U87MG and Hela cells were cultured in EMEM. DO11.10 cells were cultured in RDG
complete media composed of 45% RPMI 1640 and 45% DMEM. Jurkat cells were
cultured in RPMI 1640 supplemented with 1% L-glutamate, 1% Na pyrovate, and 2mercaptoethanol. All culture media were supplemented with 10% FBS and 1% penicillinstreptomycin (Lonza, Switzerland) and incubated at 37°C, 5% CO2. Hela, Jurkat, and
DO11.10 cells were cultured to 80% confluence for protein extraction. U87MG cells
were plated as described in “Compound Treatment” section below.
4.2. Viability Analysis
U87MG cells were cultured at 0.2X106, 0.5X106, and 1X106 for 24h and 48h. At the end
of each time point, 0.5 ml of a cell suspension was placed in a screw cap test tube and
mixed thoroughly with 0.1 ml of 0.4% Trypan Blue Stain. Cells were allowed to stand 5
min at room temperature. Dead cells, stained blue, were counted in a hemocytometer
under a microscope. Percentage of viable cells was calculated by dividing the total
number of unstained cells over the total number of cells.
4.3. Compound treatment
U87MG cells were plated at different cell numbers, as discussed in the results sections, in
2ml growth medium per well in 6-well plate. Twenty four hours later, cells were treated
with 2, 5, 10, 20, 25, and 50 μM (in DMSO) of GSI inhibitors cbz-I-L-CHO (zIL-CHO)
or N-[N-(3, 5-difluorophenacetyl)-l-alanyl]-5-phenylglycine t-butyl ester (DAPT)
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(Sigma-Aldrich) for 24, 48, and 72 hours. Additional wells were either left untreated or
treated with comparable volumes of DMSO (Sigma-Aldrich).
4.4. Protein Extraction
Whole cell lysates were prepared by lysing cells using RIPA buffer (50mM Tris, pH8.0,
150mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors).
For subcellular fractionation, total cellular protein was separated into cytoplasmic and
nuclear fractions using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific), according to manufacturer’s directions. Protein concentrations were measured
using BCA Assay kit according to manufacturer’s directions (Thermo Scientific).
4.5. Antibodies and Western Blot Analysis
Thirty to fifty micrograms of protein were separated by electrophoresis in 8% SDSpolyacrylamide gels. Proteins were electrotransferred to polyvinylidenedifluoride
membranes (PVDF) (Millipore, Bedford, MA), while either immersed in 1X transfer
buffer (wet transfer) or without transfer buffer (semi-dry transfer), and probed with the
indicated primary antibodies as shown in table 2. Horseradish peroxidase-conjugated
donkey anti-rabbit and sheep anti-mouse secondary antibodies (GE Health, Piscataway,
NJ) were used at a dilution of 1:2500, and bands were detected with enhanced
chemiluminescence (ECL, Thermo Scientific). Loading was normalized with β-Actin
(Sigma-Aldrich) for total and cytoplasmic proteins, or Histone Deacetylase 1 (HDAC1)
for nuclear proteins. Solution for blocking membranes and for primary and secondary
antibody dilutions (BLOTTO) was made from 1X PBS containing 0.1% Tween-20
supplemented with 5% (wt/vol) dry fat-free milk powder (Carnation Nestle).
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Table 2: Primary Antibody List
Antigen

Species

Clone

Dilution

Source

Notch1

Rabbit

sc-6014R

1:200

Santa Cruz

Notch1

Mouse

mN1A

1:1000

eBioscience

Cleaved Notch1

Rabbit

Polyclonal

1:1000

Cell Signaling

ADAM12

Rabbit

Polyclonal

1:1500

Proteintech

Hes1

Rabbit

Polyclonal

1:1000

Santa Cruz

c-Myc

Rabbit

Polyclonal

1:500

Santa Cruz

β-Actin

Mouse

AC-40

1:3000

Sigma-Aldrich

HDAC1

Rabbit

Polyclonal

1:1000

Cell Signaling
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4.6. Quantitative Real-time Reverse Transcription PCR (qRT-PCR)
Total RNA was isolated using mirVanaTM miRNA isolation kit (Ambion) according to
the manufacturer’s directions, and RNA concentration was measured by nanodrop
analysis. cDNA was generated from 1μg of total RNA (denatured for 5 minutes at 65°C)
in 1.2μl of dNTPs (Invitrogen), 2μl of M-MuLV reverse transcriptase buffer (New
England Biolabs), 1μl of oligo-DT (Invitrogen), 1μl RNase inhibitor (Promega) and 1μl
of 200.000 U/ml M-MuLV reverse transcriptase (New England Biolabs) performed at
42°C for 45 minutes followed by 65°C for 10 minutes using Mater Cycler Pro
(Eppendorf). cDNA for microRNAs was synthesized from 0.1μg of RNA using 1μl of
2pM of each stem loop primer. Resulting cDNA was diluted at 1:5 for total RNA genespecific amplification, undiluted for microRNA, and 1:100 for housekeeping gene (βACTIN) controls and reaction was setup using 1μl cDNA, 10μl of SYBR green mix
(Takara), 0.4μl of 10μM forward primer, 0.4μl of 10μM of reverse primer, and 8.2μl of
water. Reactions were performed in duplicates per cDNA sample using MxPRO 3000
(Stratagene) (95°C 5 min, 40 cycles [95°C X 25 sec, 62°C X 25 sec, 95°C X 1 min, 62°C
X 1 min, 95°C X 30 sec). The relative change of transcript amount in each sample was
determined by normalizing with the β-ACTIN mRNA (or Sno202 for microRNA)
expression levels using the ∆∆CT method. Primer sequences are listed in Table 3.
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Table 3: Primers for RT-PCR and qRT-PCR
Symbol

Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’)

NOTCH1

GAGGCGTGGCAGACTATGC CTTGTACTCCGTCAGCGTGA

ADAM12L

GTTTGGCTTTGGAGGAAGC
ACAG

TGCAGGCAGAGGCTTCTGAG
G

ADAM12S

CAAGGAGGCCGGATTCTG
TG

TCAGATGAGTGTCAGTGA

HES1

GAGAGGCGGCTAAGGTGTT CTGGTGTAGACGGGGATGAC
TG

β-ACTIN

GTTGTCGACGAGCG

GCACAGAGCCTGGCCTT

miR-29a

GTGCCGTACTAGCACCATC
TG

GCGACTTAGCTAACCGATTT
C

miR-29b

GGCGCGTAGCACCATTTGA
AA

GCGACACTAACCAACACTGA
T

miR-29c

GTGCCGTCCTAGCACCATT
TG

GCGACTTAGCTAACCGATTT
C

Sno202

GCTGTACTGACTTGATGAA
AG

CATCAGATGGAAAAGGCTTC
A

miR-29b
stem loop

GGTTAGACACAAGCGACAC
TAACCAACACT

miR-29ac
stem loop

GCTAAGACCATCATGCGAC
TTAGCTAACCG
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